What is 5-Amino-1MQ studied for?

Published and ongoing research looks at adipocyte size and fat mass in rodent models; nAD+ salvage-pathway activity; muscle-function research in aged animals. These are areas of study, not promised outcomes.

Is 5-Amino-1MQ FDA-approved?

5-Amino-1MQ has not been evaluated by the FDA. Elevate Chicago lists it for education and research reference only — it is not prescribed as medical care and is not intended for human consumption.

How is 5-Amino-1MQ typically used?

Oral administration is the usual route in research settings Often bundled with NAD+ precursors in marketing; the mechanisms are related but not identical Any specific dose, frequency or duration comes from a prescription written for you after labs — never from this page.

What are the risks and unknowns with 5-Amino-1MQ?

Research use only; not FDA-approved No published human trials NNMT has roles beyond fat tissue that inhibition may affect

Metabolic & body composition

5-Amino-1MQ

Written by the Elevate Clinical Team

Citations independently verified against PubMed, ClinicalTrials.gov, and FDA sources on August 19, 2026. Independent clinical review pending.

A small-molecule NNMT inhibitor studied for fat-cell metabolism and NAD+ availability.

What it is

5-Amino-1MQ inhibits nicotinamide N-methyltransferase (NNMT), an enzyme elevated in obese adipose tissue. Blocking it in animal models increases intracellular NAD+ and shrinks fat cells without changing food intake. It is a small molecule, not a peptide, and it is orally available.

What it's studied for

Adipocyte size and fat mass in rodent models
NAD+ salvage-pathway activity
Muscle-function research in aged animals

How it's used in practice

Oral administration is the usual route in research settings
Often bundled with NAD+ precursors in marketing; the mechanisms are related but not identical

What you should know before asking about it

Research use only; not FDA-approved
No published human trials
NNMT has roles beyond fat tissue that inhibition may affect

Frequently asked questions.

What is 5-Amino-1MQ?: 5-Amino-1MQ inhibits nicotinamide N-methyltransferase (NNMT), an enzyme elevated in obese adipose tissue. Blocking it in animal models increases intracellular NAD+ and shrinks fat cells without changing food intake. It is a small molecule, not a peptide, and it is orally available.
What is 5-Amino-1MQ studied for?: Published and ongoing research looks at adipocyte size and fat mass in rodent models; nAD+ salvage-pathway activity; muscle-function research in aged animals. These are areas of study, not promised outcomes.
Is 5-Amino-1MQ FDA-approved?: 5-Amino-1MQ has not been evaluated by the FDA. Elevate Chicago lists it for education and research reference only — it is not prescribed as medical care and is not intended for human consumption.
How is 5-Amino-1MQ typically used?: Oral administration is the usual route in research settings Often bundled with NAD+ precursors in marketing; the mechanisms are related but not identical Any specific dose, frequency or duration comes from a prescription written for you after labs — never from this page.
What are the risks and unknowns with 5-Amino-1MQ?: Research use only; not FDA-approved No published human trials NNMT has roles beyond fat tissue that inhibition may affect

Sources

1.Published literature on 5-Amino-1MQ— PubMed, U.S. National Library of Medicine
2.Compounding and the FDA: questions and answers— U.S. Food & Drug Administration
3.Bulk drug substances nominated for use in compounding under section 503A— U.S. Food & Drug Administration
4.Test directory and patient service center locator— Quest Diagnostics

About this page

Written by the Elevate Clinical Team

Citations independently verified against PubMed, ClinicalTrials.gov, and FDA sources on August 19, 2026. Independent clinical review pending. Educational content only — not medical advice, not a diagnosis, and not an offer to sell any prescription product.

This page is educational reference material. It is not medical advice, not a diagnosis, and not an offer to sell any product. Prescription therapies are dispensed only through licensed, FDA-registered compounding pharmacies after a physician evaluation. Compounds identified as research use only are not FDA-approved, are not prescribed as medical care, and are not intended for human or animal consumption. Availability, formulations and regulatory status change over time.

Begin your intake Peptide therapy overview

Single Regulator (GLP-1) — semaglutide

Semaglutide, listed as Single Regulator (GLP-1) because compounded formulations cannot be marketed under the drug's commercial name. A GLP-1 medication containing an active ingredient also found in FDA-approved products; compounded formulations are not themselves FDA-approved.

Dual Regulator (GLP-1/GIP) — tirzepatide

Tirzepatide, listed as Dual Regulator (GLP-1/GIP) because compounded formulations cannot be marketed under the drug's commercial name. A GIP/GLP-1 medication containing an active ingredient also found in FDA-approved products; compounded formulations are not themselves FDA-approved.

Triple Regulator (GLP-1/GIP/glucagon)

An investigational triple agonist (GLP-1, GIP and glucagon) in late-stage clinical trials — not approved, not prescribable.

View the full peptide library